S&P 500 climbs, but Nvidia slip keeps lid on gains
Johnson & Johnson (NYSE:JNJ), through its subsidiary Johnson & Johnson Innovation - JJDC, Inc., sold 52,532 shares of CVRx, Inc. (NASDAQ:CVRX) common stock on November 6 and 7, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales totaled $536,309.
The shares were sold at prices ranging from $10.00 to $10.49 on November 6, and at $10.00 on November 7. Following these transactions, Johnson & Johnson Innovation - JJDC, Inc. indirectly holds 4,050,898 shares of CVRx.
In other recent news, CVRx Inc. reported its third-quarter 2025 financial results, revealing revenue of $14.7 million, marking a 10% increase compared to the previous year. This revenue figure exceeded analyst expectations, including Cantor Fitzgerald’s estimate of $14.5 million and Canaccord Genuity’s projection of $14.3 million. The company’s earnings per share (EPS) showed a loss of $0.49, which was slightly better than the anticipated loss of $0.50. Following these results, Cantor Fitzgerald raised its price target for CVRx to $13, maintaining an Overweight rating. Similarly, Canaccord Genuity increased its price target to $11, up from $9, while retaining a Buy rating. These developments reflect the company’s ability to outperform revenue expectations, despite a slight dip in its stock price during after-hours trading. The U.S. revenue for CVRx reached $13.5 million, surpassing Canaccord’s forecast of $13.4 million. These recent developments highlight the company’s ongoing financial performance and the positive outlook from analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.